1. Home
  2. RAIN

RAIN

Rain Oncology Inc.

Logo Rain Oncology Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

0

Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Founded: 2017 Country:
United States
United States
Employees: N/A City: NEWARK
Market Cap: 44.8M IPO Year: 2021
Target Price: $6.87 AVG Volume (30 days): 238.3K
Analyst Decision: Buy Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.07 EPS Growth: N/A
52 Week Low/High: $0.82 - $11.32 Next Earning Date: 03-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: